Imricor Medical Systems Announces Sales Collaboration with Optoacoustics

Imricor Medical Systems has announced a sales collaboration with Optoacoustics Ltd, the world leader in innovative, high-performance optical communication solutions for magnetic resonance (MR) applications.

The collaboration establishes a formal relationship between Imricor Medical Systems and Optoacoustics to facilitate the introduction of the IMROC IRTM Wireless Multichannel Communication System to Imricor customers. IMROC provides wireless noise-canceling MRI headsets that can be used by up to 8 participants simultaneously, including the patient. The system was developed specifically for use in iCMR environments.

Given the noise and complexities of MRI, normal conversation can be difficult during iCMR procedures. The IMROC IR System is the first multi-channel wireless audio system in the world to operate without RF. The system uses light waves for transmission with no impact on MRI imaging, enabling calm, clear dialog between doctors and technicians.

“Optoacoustics is a well-known company in the communication space. The technology is very innovative and supports our overall strategy of bringing cardiac interventions into the iCMR,” said Nick Twohy, Imricor’s Director of Marketing.

Imricor products are specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. Imricor is the first and only company to offer cardiac ablation devices for use in the MRI environment.

Dr. Yuvi Kahana, CEO and Co-Founder of Optoacoustics, stated, “We’re thrilled and excited – it’s hard to imagine a better fit for IMROC. Imricor’s advances in cardiac catheter ablation highlight the productive benefits of simple, comfortable communications among iCMR staff, and IMROC provides the most effective and robust noise cancelling solution available.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version